亿帆医药股份有限公司关于公司产品获批的公告

Group 1 - Company’s subsidiary, Hangzhou Xinfu Technology Co., Ltd., received approval from the National Health Commission for 2'-Fucosyllactose as a food nutrition enhancer [1][2] - 2'-Fucosyllactose is a significant oligosaccharide found in breast milk, known for its benefits in regulating gut microbiota, promoting brain development, and enhancing immunity [1] - The approval allows the use of 2'-Fucosyllactose in various infant formula products, including those for special medical purposes [2] Group 2 - The approval marks a significant advancement in the application of synthetic biology for the company, laying a solid foundation for future product commercialization [3] - The company has adjusted guarantee limits among its subsidiaries, reallocating unused guarantee amounts to support business development needs [5][6] - The company provided guarantees totaling RMB 15 million to China Bank and RMB 20 million to China Merchants Bank for its subsidiary Hefei Yifan Biopharmaceutical Co., Ltd. [7] Group 3 - The total external guarantee balance after the new guarantees is RMB 46.12 billion, representing 54.12% of the company's audited net assets for 2024 [27] - The guarantees are exclusively between the company and its subsidiaries, with no overdue guarantees or litigation-related guarantee amounts reported [27]